U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Adial Pharmaceuticals

Market Cap: US$7.6m

A clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.

Psyence Biomedical

Market Cap: US$1.5m

Engages in the development of botanical psilocybin-based psychedelic medicines.

Supernus Pharmaceuticals

Market Cap: US$2.5b

A biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States.

Metagenomi

Market Cap: US$66.8m

A genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.

Aclaris Therapeutics

Market Cap: US$224.2m

A clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.

Reflect Scientific

Market Cap: US$5.1m

Through its subsidiaries, engages in the design, development, and sale of scientific equipment for the life science and manufacturing industries worldwide.

Apollomics

Market Cap: US$6.0m

A clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer.

GRAIL

Market Cap: US$1.2b

A commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.

Quanterix

Market Cap: US$200.7m

A life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions.

Bio-Techne

Market Cap: US$8.2b

Develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.

Inhibitor Therapeutics

Market Cap: US$6.6m

A pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States.

InflaRx

Market Cap: US$106.4m

A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.

Stoke Therapeutics

Market Cap: US$1.1b

An early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.

Apogee Therapeutics

Market Cap: US$2.2b

A clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications.

Xenon Pharmaceuticals

Market Cap: US$3.0b

A neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada.

Black Diamond Therapeutics

Market Cap: US$163.4m

A clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors.

Zura Bio

Market Cap: US$134.6m

A clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States.

Fulcrum Therapeutics

Market Cap: US$372.2m

A clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.

Neurocrine Biosciences

Market Cap: US$13.9b

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.

Cabaletta Bio

Market Cap: US$140.9m

A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.

Elite Pharmaceuticals

Market Cap: US$760.2m

A specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals.

Aura Biosciences

Market Cap: US$398.8m

A clinical-stage biotechnology company, develops precision therapies to treat solid tumors.

Opus Genetics

Market Cap: US$80.7m

A clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs).

Larimar Therapeutics

Market Cap: US$331.2m

A clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.

Spyre Therapeutics

Market Cap: US$1.0b

A clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD).

SIGA Technologies

Market Cap: US$607.9m

A commercial-stage pharmaceutical company, focuses on the health security market in the United States.

Terns Pharmaceuticals

Market Cap: US$631.8m

A clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity.

Fate Therapeutics

Market Cap: US$116.5m

A clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.

Eledon Pharmaceuticals

Market Cap: US$162.3m

Operates as a clinical stage biotechnology company.

MediciNova

Market Cap: US$63.3m

A biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.

CytoMed Therapeutics

Market Cap: US$22.3m

A pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.

Cidara Therapeutics

Market Cap: US$1.6b

Operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases.

Sera Prognostics

Market Cap: US$127.1m

A women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States.

Sunshine Biopharma

Market Cap: US$6.2m

Operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.

Y-mAbs Therapeutics

Market Cap: US$389.9m

A commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer.

Burning Rock Biotech

Market Cap: US$89.4m

Develops and sells cancer therapy selection tests in the People's Republic of China and the United States.